Clinical trials: Neoplasms Recurrence
Head and Neck Squamous Cell Carcinoma
Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)
To assess response rate of docetaxel and S-1 combination in metastatic or recurrent head and neck squamous cell carcinoma
- Trial name
- NCT00805012
- Testing
- docetaxel+CDDP, docetaxel+S-1
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Seoul National University Hospital
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Hepatocellular Carcinoma
Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.
- Trial name
- NCT01266707
- Testing
- antiangiogenic paptide vaccine
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Fukushima Medical University
B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma
- Trial name
- NCT00010192
- Testing
- rituximab, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Recurrent, Refractory
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, preliminary efficacy, pharmacokinetics of universal T-cells engineered with chimeric natural killer…
- Trial name
- NCT06751134
- Testing
- Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Nanjing Children's Hospital
Nasopharyngeal Carcinoma
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
This is an open-label, single center, non-randomized, phase I trial to evaluate the safety and efficacy of gemcitabine combined with apatinib and toripalimab in patients with the recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT04073784
- Testing
- Gemcitabine combined with Aptinib and Toripalimab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
This is a randomized phase II study trial that has served as a screening trial to test the increased efficacy of chemotherapy + cetuximab versus chemotherapy alone among patients with untreated, advanced or metastatic colon…
- Trial name
- NCT00077233
- Testing
- cetuximab, 5-FU, irinotecan
- Where
- 77 sites in United States
- Volunteers
- 238 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
This phase I trial is studying the side effects and best dose of temsirolimus when given together with dexamethasone in treating patients with recurrent or refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00693433
- Testing
- dexamethasone, temsirolimus, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow.
- Trial name
- NCT00238433
- Testing
- filgrastim, busulfan, melphalan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- OHSU Knight Cancer Institute
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
RATIONALE: Taking part in a clinical trial may help children with cancer receive more effective treatment. PURPOSE: Determine why patients who are eligible for protocols made available through the Pediatric Oncology Group do not…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia
- Trial name
- NCT00002485
- Testing
- psychosocial assessment and care
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 359 people
- Sponsor
- Children's Oncology Group
Renal Cell Cancer
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
This research study is for subjects with cancer of the kidney (also known as renal cell carcinoma) that cannot be treated with surgery.
- Trial name
- NCT00184015
- Testing
- Bevacizumab and Bortezomib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Southern California
Metastatic Sarcoma
A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas
The purpose of this study is to find out what effects a new drug SB939 has on you and your sarcoma. This research is being done because there is a need for better treatment options for advanced or recurring sarcoma.
- Trial name
- IND200 (NCT01112384)
- Testing
- SB939
- Where
- 8 sites in Canada
- Volunteers
- 24 people
- Sponsor
- NCIC Clinical Trials Group
Cervical Cancer, Endometrial Cancer
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00842452
- Testing
- topotecan hydrochloride, pharmacological study
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Steven Waggoner, MD
Recurrent Breast Cancer, Metastatic Breast Cancer
B002 in Patients With HER2-positive Breast Cancer
To assess the safety and tolerability characteristics of B002 in patients with HER2-positive recurrent or metastatic breast cancer. The dose-limiting toxicity (DLT) was assessed and the maximum tolerated dose (MTD) was explored.
- Trial name
- B002-101 (NCT04382352)
- Testing
- Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
This randomized phase II trial studies how well megestrol acetate or levonorgestrel-releasing intrauterine system works in treating patients with atypical endometrial hyperplasia or endometrial cancer.
- Conditions
- Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IA Endometrial Carcinoma
- Trial name
- NCT01943058
- Testing
- megestrol acetate, levonorgestrel-releasing intrauterine system, laboratory biomarker analysis
- Sponsor
- University of Southern California
Leukemia
Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myelogenous leukemia cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients with acute myelogenous…
- Trial name
- NCT00003148
- Testing
- aldesleukin
- Where
- 10 sites in Austria, Belgium and 4 more
- Volunteers
- 86 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Adult
Lentivirally Redirected CD123 Autologous T Cells in AML
Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and…
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia, Refractory
- Trial name
- NCT03766126
- Testing
- CART123 cells; cyclophosphamide; fludarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00002515
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Minimal Residual Disease, Leukemia, Lymphoblastic, Acute
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete…
- Conditions
- Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute
- Trial name
- NCT01158885
- Testing
- Clofarabine, Cytarabine intravenous, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.